P/E ratio for Clovis Oncology (CLVS)
P/E ratio as of April 2024 (TTM): -0.0430
According to Clovis Oncology's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.042963. At the end of 2012 the company had a P/E ratio of -5.35.
P/E ratio history for Clovis Oncology from 2012 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2012 | -5.35 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -24,247.76% | 🇺🇸 USA |
 Pfizer PFE | 13.7 | -31,872.69% | 🇺🇸 USA |
 AbbVie ABBV | 43.4 | -101,041.04% | 🇺🇸 USA |
 Eli Lilly LLY | 135 | -314,151.63% | 🇺🇸 USA |
 AstraZeneca AZN | 37.9 | -88,243.29% | 🇬🇧 UK |
 BioMarin Pharmaceutical BMRN | 104 | -242,301.43% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.